Clinical Trial Detail

NCT ID NCT02747043
Title Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Amgen
Indications

follicular lymphoma

Therapies

ABP 798

Rituximab

Age Groups: adult senior

No variant requirements are available.